---
title: "apollo"
date: "2024-08-25"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[acute promyelocytic leukemia (APL)]]

# apollo

APOLLO trial (NCT02688140): ATRA/ATO + idarubicin vs. ATRA/chemotherapy, Event-free survival (EFS) at 2 years: 88% vs. 70% (P = .02), and at 5 years: 87% vs. 55% (P = .0034); hematologic toxicity was significantly lower in the ATRA/ATO arm.

- [ATRA/ATO Regimen Improves EFS in Newly Diagnosed, High-risk APL](https://www.onclive.com/view/atra-ato-regimen-improves-efs-in-newly-diagnosed-high-risk-apl)
- [EHA Library - The official digital education library of European Hematology Association (EHA)](https://library.ehaweb.org/eha/2024/eha2024-congress/422206/uwe.platzbecker.first.results.of.the.apollo.trial.a.randomized.phase.iii.study.html)
